Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease

Background: Dexmedetomidine is frequently used for sedation during deep brain stimulator implantation in patients with Parkinson's disease, but its effect on subthalamic nucleus activity is not well known. The aim of this study was to quantify the effect of increasing doses of dexmedetomidine i...

Full description

Bibliographic Details
Main Authors: Martinez-Simon, A. (Antonio), Valencia, M. (Miguel), Cacho-Asenjo, E. (Elena), Honorato-Cía, C. (Cristina), Nuñez-Cordoba, J.M. (Jorge M.), Manzanilla-Zapata, Ó. (Óscar), Aldaz, A. (Azucena), Panadero-Sánchez, A. (Alfredo), Guridi-Legarra, J. (Jorge), Alegre-Esteban, M. (Manuel)
Format: info:eu-repo/semantics/article
Language:eng
Published: Elsevier 2022
Subjects:
Online Access:https://hdl.handle.net/10171/63366
_version_ 1793399907852222464
author Martinez-Simon, A. (Antonio)
Valencia, M. (Miguel)
Cacho-Asenjo, E. (Elena)
Honorato-Cía, C. (Cristina)
Nuñez-Cordoba, J.M. (Jorge M.)
Manzanilla-Zapata, Ó. (Óscar)
Aldaz, A. (Azucena)
Panadero-Sánchez, A. (Alfredo)
Guridi-Legarra, J. (Jorge)
Alegre-Esteban, M. (Manuel)
author_facet Martinez-Simon, A. (Antonio)
Valencia, M. (Miguel)
Cacho-Asenjo, E. (Elena)
Honorato-Cía, C. (Cristina)
Nuñez-Cordoba, J.M. (Jorge M.)
Manzanilla-Zapata, Ó. (Óscar)
Aldaz, A. (Azucena)
Panadero-Sánchez, A. (Alfredo)
Guridi-Legarra, J. (Jorge)
Alegre-Esteban, M. (Manuel)
author_sort Martinez-Simon, A. (Antonio)
collection DSpace
description Background: Dexmedetomidine is frequently used for sedation during deep brain stimulator implantation in patients with Parkinson's disease, but its effect on subthalamic nucleus activity is not well known. The aim of this study was to quantify the effect of increasing doses of dexmedetomidine in this population. Methods: Controlled clinical trial assessing changes in subthalamic activity with increasing doses of dexmedetomidine (from 0.2 to 0.6 μg kg-1 h-1) in a non-operating theatre setting. We recorded local field potentials in 12 patients with Parkinson's disease with bilateral deep brain stimulators (24 nuclei) and compared basal activity in the nuclei of each patient and activity recorded with different doses. Plasma levels of dexmedetomidine were obtained and correlated with the dose administered. Results: With dexmedetomidine infusion, patients became clinically sedated, and at higher doses (0.5-0.6 μg kg-1 h-1) a significant decrease in the characteristic Parkinsonian subthalamic activity was observed (P<0.05 in beta activity). All subjects awoke to external stimulus over a median of 1 (range: 0-9) min, showing full restoration of subthalamic activity. Dexmedetomidine dose administered and plasma levels showed a positive correlation (repeated measures correlation coefficient=0.504; P<0.001). Conclusions: Patients needing some degree of sedation throughout subthalamic deep brain stimulator implantation for Parkinson's disease can probably receive dexmedetomidine up to 0.6 μg kg-1 h-1 without significant alteration of their characteristic subthalamic activity. If patients achieve a 'sedated' state, subthalamic activity decreases, but they can be easily awakened with a non-pharmacological external stimulus and recover baseline subthalamic activity patterns in less than 10 min.
format info:eu-repo/semantics/article
id oai:dadun.unav.edu:10171-63366
institution Universidad de Navarra
language eng
publishDate 2022
publisher Elsevier
record_format dspace
spelling oai:dadun.unav.edu:10171-633662023-12-15T11:27:51Z Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease Martinez-Simon, A. (Antonio) Valencia, M. (Miguel) Cacho-Asenjo, E. (Elena) Honorato-Cía, C. (Cristina) Nuñez-Cordoba, J.M. (Jorge M.) Manzanilla-Zapata, Ó. (Óscar) Aldaz, A. (Azucena) Panadero-Sánchez, A. (Alfredo) Guridi-Legarra, J. (Jorge) Alegre-Esteban, M. (Manuel) Parkinson's disease Deep brain stimulation Dexmedetomidine Local field potentials Sedation Subthalamic activity Background: Dexmedetomidine is frequently used for sedation during deep brain stimulator implantation in patients with Parkinson's disease, but its effect on subthalamic nucleus activity is not well known. The aim of this study was to quantify the effect of increasing doses of dexmedetomidine in this population. Methods: Controlled clinical trial assessing changes in subthalamic activity with increasing doses of dexmedetomidine (from 0.2 to 0.6 μg kg-1 h-1) in a non-operating theatre setting. We recorded local field potentials in 12 patients with Parkinson's disease with bilateral deep brain stimulators (24 nuclei) and compared basal activity in the nuclei of each patient and activity recorded with different doses. Plasma levels of dexmedetomidine were obtained and correlated with the dose administered. Results: With dexmedetomidine infusion, patients became clinically sedated, and at higher doses (0.5-0.6 μg kg-1 h-1) a significant decrease in the characteristic Parkinsonian subthalamic activity was observed (P<0.05 in beta activity). All subjects awoke to external stimulus over a median of 1 (range: 0-9) min, showing full restoration of subthalamic activity. Dexmedetomidine dose administered and plasma levels showed a positive correlation (repeated measures correlation coefficient=0.504; P<0.001). Conclusions: Patients needing some degree of sedation throughout subthalamic deep brain stimulator implantation for Parkinson's disease can probably receive dexmedetomidine up to 0.6 μg kg-1 h-1 without significant alteration of their characteristic subthalamic activity. If patients achieve a 'sedated' state, subthalamic activity decreases, but they can be easily awakened with a non-pharmacological external stimulus and recover baseline subthalamic activity patterns in less than 10 min. 2022-04-06T12:55:20Z 2022-04-06T12:55:20Z 2021 info:eu-repo/semantics/article https://hdl.handle.net/10171/63366 eng info:eu-repo/semantics/openAccess application/pdf Elsevier
spellingShingle Parkinson's disease
Deep brain stimulation
Dexmedetomidine
Local field potentials
Sedation
Subthalamic activity
Martinez-Simon, A. (Antonio)
Valencia, M. (Miguel)
Cacho-Asenjo, E. (Elena)
Honorato-Cía, C. (Cristina)
Nuñez-Cordoba, J.M. (Jorge M.)
Manzanilla-Zapata, Ó. (Óscar)
Aldaz, A. (Azucena)
Panadero-Sánchez, A. (Alfredo)
Guridi-Legarra, J. (Jorge)
Alegre-Esteban, M. (Manuel)
Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease
title Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease
title_full Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease
title_fullStr Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease
title_full_unstemmed Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease
title_short Effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease
title_sort effects of dexmedetomidine on subthalamic local field potentials in parkinson's disease
topic Parkinson's disease
Deep brain stimulation
Dexmedetomidine
Local field potentials
Sedation
Subthalamic activity
url https://hdl.handle.net/10171/63366
work_keys_str_mv AT martinezsimonaantonio effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT valenciammiguel effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT cachoasenjoeelena effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT honoratociaccristina effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT nunezcordobajmjorgem effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT manzanillazapataooscar effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT aldazaazucena effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT panaderosanchezaalfredo effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT guridilegarrajjorge effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease
AT alegreestebanmmanuel effectsofdexmedetomidineonsubthalamiclocalfieldpotentialsinparkinsonsdisease